A Phase 3 interventional study of EpiCeram in Eczema, Asthma and Allergy;Food, sponsored by University of Melbourne. Active, not recruiting at 4 sites in Australia. Open to participants aged Up to 3 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-10.
Sponsored by University of Melbourne · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Eczema with a site in Australia — 4 open to participants now, 9 under way, 3 of them phase 3. Eczema · Australia.
Among the 41 studies in Eczema with a site in Australia, this one is the 8th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2018, is one of 22 in phase 3, and was the 11th registered.
507 studies on the registry are indexed under Eczema; 91 are open to participants now.
Browse Eczema studies →4 of the 41 studies in Eczema with a site in Australia are open now. Recruiting first, the newest first:
Inmagene LLC · Sites in Australia, United States, Canada and 1 more country
Ages 18–74
Alphyn Biologics · Sites in Australia
Ages 2+
The University of New South Wales · Sites in Australia
Ages 3 mo–3 yrs
Eli Lilly and Company · Sites in Australia, United States, Argentina and 10 more countries
Ages 6 mo–18 yrs
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: Up to 3 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 17 · Phase 3 22 · Phase 4 1
First in 2006; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 760 is above the median of 91 across 404 interventional studies indexed under Eczema.
Median enrollment 389 across the 40 interventional studies. Of the 31 that completed or were terminated, 25 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 41 have an industry lead sponsor. The 10 most frequent:
University of Melbourne is the lead sponsor of 87 studies on the registry; 23 are open to participants now.
University of Melbourne has 1 study filed under Eczema — fewer than ten, so there is no comparison to draw.
1 of the studies in Eczema with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03667651Phase 3University of MelbourneThe PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Eczema with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants.
A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.
The primary objective of this study is to demonstrate that twice daily application of a ceramide dominant emollient reduces the risk of eczema and food allergy, when compared to standard skin management. Secondary objectives are to determine if twice daily application of a ceramide dominant emollient reduces the risk of infants developing allergic sensitisation (as measured by skin prick test); to determine if twice daily application of a ceramide dominant emollient improves infant skin barrier function; to determine the level of parental compliance with a program to build infant skin barrier function; to confirm that a ceramide dominant emollient does not cause adverse effects in infants; to determine the level of compliance required to demonstrate an improvement in infant skin barrier function and to determine if twice daily application of a ceramide dominant emollient influences infant skin microbial colonisation, or skin lipid profile.
This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants.
A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.
Treatment will be from birth until six months, with a six week, six month and twelve month follow-up. An initial assessment will be performed at baseline which incorporates three surveys, a skin assessment, diary card (which is to be completed weekly and measures compliance), a breast milk sample, guthrie card and tape stripping. The six week and six month assessments entail a skin assessment, survey, compliance check, breast milk sample, tape stripping and guthrie card. Primary outcomes are assessed at the 12 month follow up where in addition to the aforementioned items, a saliva sample will also be taken and skin prick testing and food challenges will be performed when children have a positive SPT to one or more foods..
Inclusion Criteria:
Infants will be eligible for this study if their mother, father, or an older sibling has a self-reported history of at least one of the following conditions:
Exclusion Criteria: infants with any of the following will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.
Drug: EpiCeram
Parents are to follow standard skin care practices
Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
Presence of eczema
as assessed using i) the UK working party criteria for eczema and/or ii) blinded investigator observed eczema.
Time frame: 12 months of age.
Confirmed diagnosis of food allergy at 12 months (52 weeks).
This diagnosis is derived from a combination of allergic sensitisation, reaction history and food challenge. A skin prick test to six common allergens will be performed (egg white, cows' milk, peanut, dust mite, cat dander, and rye grass) along with a negative (saline) and a positive (histamine) control. Participants that are sensitised to certain foods (\>=1mm wheal) during the skin prick testing will be given a challenge to determine if they are allergic to those foods. This will be conducted at the MCRI Allergy Clinic under the supervision of a Doctor specifically trained in oral food challenges.
Time frame: 12 months of age
Eczema severity
assessed using the EASI score
Time frame: 12 months of age
Parent report of a community doctor diagnosis of eczema
Time frame: 12 months of age
infant skin barrier function
As assessed by Trans-epidermal water loss (Vapometer)
Time frame: At 6 weeks and 12 months of age
Parental compliance with a program to build infant skin barrier function
as assessed by parental completion of weekly diary cards and weighing of the tubes of study cream at each visit
Time frame: At 6 weeks and 6 months of age.
Adverse events
as assessed by the documentation of any untoward medical occurrence in a participant enrolled into this study
Time frame: From recruitment of infant until final study visit at 12 months of age.
skin microbial colonisation, or skin lipid profile
Assessed using skin swabs at baseline, 6 weeks and 12 months of age
Time frame: At 6 weeks and 6 and 12 months of age
Plan to share: Undecided
Started Mar 2018 (actual). Primary completion is estimated for May 2027, 110 months after the start.
Of 71 phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 110 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EpiCeram
University of Melbourne